BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 27510985)

  • 1. Effect of hesperidin on the pharmacokinetics of CPT-11 and its active metabolite SN-38 by regulating hepatic Mrp2 in rats.
    Wang X; Rao Z; Qin H; Zhang G; Ma Y; Jin Y; Han M; Shi A; Wang Y; Wu X
    Biopharm Drug Dispos; 2016 Oct; 37(7):421-432. PubMed ID: 27510985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats.
    Arimori K; Kuroki N; Hidaka M; Iwakiri T; Yamsaki K; Okumura M; Ono H; Takamura N; Kikuchi M; Nakano M
    Pharm Res; 2003 Jun; 20(6):910-7. PubMed ID: 12817897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loperamide inhibits the biliary excretion of irinotecan (CPT-11) in the rat isolated perfused liver.
    Tobin PJ; Hong Y; Seale JP; Rivory LP; McLachlan AJ
    J Pharm Pharmacol; 2005 Jan; 57(1):39-45. PubMed ID: 15638991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein.
    Sugiyama Y; Kato Y; Chu X
    Cancer Chemother Pharmacol; 1998; 42 Suppl():S44-9. PubMed ID: 9750028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biliary excretion of irinotecan and its metabolites.
    Itoh T; Takemoto I; Itagaki S; Sasaki K; Hirano T; Iseki K
    J Pharm Pharm Sci; 2004 Jan; 7(1):13-8. PubMed ID: 15144730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of poly (ethylene oxide)-poly (propylene oxide)-poly (ethylene oxide) micelles on pharmacokinetics and intestinal toxicity of irinotecan hydrochloride: potential involvement of breast cancer resistance protein (ABCG2).
    Guo S; Zhang X; Gan L; Zhu C; Gan Y
    J Pharm Pharmacol; 2010 Aug; 62(8):973-84. PubMed ID: 20663031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of up-regulation of hepatic breast cancer resistance protein in decreased plasma concentration of 7-ethyl-10-hydroxycamptothecin (SN-38) by coadministration of S-1 in rats.
    Yokoo K; Hamada A; Watanabe H; Matsuzaki T; Imai T; Fujimoto H; Masa K; Imai T; Saito H
    Drug Metab Dispos; 2007 Sep; 35(9):1511-7. PubMed ID: 17537871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats.
    Chu XY; Kato Y; Niinuma K; Sudo KI; Hakusui H; Sugiyama Y
    J Pharmacol Exp Ther; 1997 Apr; 281(1):304-14. PubMed ID: 9103511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic mechanisms for reduced toxicity of irinotecan by coadministered thalidomide.
    Yang XX; Hu ZP; Chan SY; Duan W; Ho PC; Boelsterli UA; Ng KY; Chan E; Bian JS; Chen YZ; Huang M; Zhou SF
    Curr Drug Metab; 2006 May; 7(4):431-55. PubMed ID: 16724931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic modulation of irinotecan metabolites by sulphobromophthalein in rats.
    Itoh T; Itagaki S; Sasaki K; Hirano T; Takemoto I; Iseki K
    J Pharm Pharmacol; 2004 Jun; 56(6):809-12. PubMed ID: 15231047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats.
    Takasuna K; Hagiwara T; Hirohashi M; Kato M; Nomura M; Nagai E; Yokoi T; Kamataki T
    Cancer Chemother Pharmacol; 1998; 42(4):280-6. PubMed ID: 9744772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor.
    Yang XX; Hu ZP; Xu AL; Duan W; Zhu YZ; Huang M; Sheu FS; Zhang Q; Bian JS; Chan E; Li X; Wang JC; Zhou SF
    J Pharmacol Exp Ther; 2006 Oct; 319(1):82-104. PubMed ID: 16815871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats.
    Horikawa M; Kato Y; Sugiyama Y
    Pharm Res; 2002 Sep; 19(9):1345-53. PubMed ID: 12403072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients.
    Slatter JG; Schaaf LJ; Sams JP; Feenstra KL; Johnson MG; Bombardt PA; Cathcart KS; Verburg MT; Pearson LK; Compton LD; Miller LL; Baker DS; Pesheck CV; Lord RS
    Drug Metab Dispos; 2000 Apr; 28(4):423-33. PubMed ID: 10725311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of genistein, a natural soy isoflavone, on the pharmacokinetics and intestinal toxicity of irinotecan hydrochloride in rats.
    Yokooji T; Kawabe Y; Mori N; Murakami T
    J Pharm Pharmacol; 2013 Feb; 65(2):280-91. PubMed ID: 23278696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of β-glucuronidase activity in intestinal lumen.
    Kurita A; Kado S; Matsumoto T; Asakawa N; Kaneda N; Kato I; Uchida K; Onoue M; Yokokura T
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):201-13. PubMed ID: 20354702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Intraperitoneal administration of CPT-11 in rats--experimental study for pharmacokinetics].
    Nagahama T; Maruyama M; Goseki N
    Gan To Kagaku Ryoho; 2000 Oct; 27(12):1866-9. PubMed ID: 11086432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters.
    Chu XY; Kato Y; Ueda K; Suzuki H; Niinuma K; Tyson CA; Weizer V; Dabbs JE; Froehlich R; Green CE; Sugiyama Y
    Cancer Res; 1998 Nov; 58(22):5137-43. PubMed ID: 9823324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Food-drug interaction of (-)-epigallocatechin-3-gallate on the pharmacokinetics of irinotecan and the metabolite SN-38.
    Lin LC; Wang MN; Tsai TH
    Chem Biol Interact; 2008 Aug; 174(3):177-82. PubMed ID: 18579105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of SN-38 [(+)-(4S)-4,11-diethyl-4,9-dihydroxy-1H- pyrano[3',4':6,7]-indolizino[1,2-b]quinoline-3,14(4H,12H)-dione], an active metabolite of irinotecan, after a single intravenous dosing of 14C-SN-38 to rats.
    Atsumi R; Okazaki O; Hakusui H
    Biol Pharm Bull; 1995 Aug; 18(8):1114-9. PubMed ID: 8535406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.